BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells.

ABSTRACT:

Purpose

BRAF and MEK inhibitors (BRAFi and MEKi) are actively used for the treatment of metastatic melanoma in patients with BRAF^V600E mutation in their tumors. However, the development of resistance to BRAFi and MEKi remains a difficult clinical challenge with limited therapeutic options available to these patients. In this study, we investigated the mechanism and potential therapeutic utility of combination BRAFi and adoptive T-cell therapy (ACT) in melanoma resistant to BRAFi.

Experimental design

Investigations were performed in vitro and in vivo with various human melanoma cell lines sensitive and resistant to BRAFi as well as patient-derived xenografts (PDX) derived from patients. In addition, samples were evaluated from patients on a clinical t

SUBMITTER: Atay C 

PROVIDER: S-EPMC6497575 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature